ArticleAlimentary pharmacology & therapeutics2026
Risk Prediction of Early-Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk Prediction of Early-Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe global incidence of early-onset hepatocellular carcinoma (eHCC) is increasing significantly; however, specific risk prediction tools for young adults remain scarce. This study aimed to develop and validate predictive models for eHCC using both conventional statistical and machine learning techniques.
methodsWe included 1,756,593 young adults aged 20-39 years who underwent health screenings in South Korea between 2013 and 2014 with follow-up until January 31, 2022. Participants were randomly divided into training and validation sets (1:1 ratio). Prediction models were constructed using cause-specific Cox proportional hazards regression, Fine-Gray subdistribution hazards regression, generalized boosted model (GBM), and generalized boosted survival model (GBM-survival).
resultsKey predictors of eHCC in the training cohort included viral hepatitis, history of non-HCC cancer, liver cirrhosis, and gamma-glutamyl transferase. In the validation cohort, GBM-survival demonstrated best predictive performance for eHCC in young adults, with area under the receiver operating characteristic curves (auROCs) of 0.945 (1-year) and 0.825 (5-year). The most significant features in GBM-survival were aspartate aminotransferase level, history of non-HCC cancer, viral hepatitis, gamma-glutamyl transferase, and serum creatinine. A global surrogate model for the GBM-survival model enhanced interpretability (RMSE = 0.287; Pearson r = 0.887). Using the K-group method, GBM-survival achieved risk ratios of 2092.3 and 166.2 for 1-year and 5-year eHCC prediction, respectively.
conclusionsWe developed and validated robust risk prediction models for eHCC that integrated established risk factors with emerging metabolic indicators. This study provides actionable tools for risk stratification in young adults to address the growing burden of eHCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.